Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma

被引:28
作者
Tom, Greeshma [1 ,4 ]
Philip, Sheena [1 ,4 ]
Isaac, Rimal [2 ]
Praseetha, P. K. [2 ]
Jiji, S. G. [3 ]
Asha, V. V. [1 ]
机构
[1] Rajiv Gandhi Ctr Biotechnol, Plant Based Bioact & Dis Biol Lab, Thiruvananthapuram 695014, Kerala, India
[2] Noorul Islam Ctr Higher Educ, Dept Nanotechnol, Kumaracoil 629180, Tamil Nadu, India
[3] Univ Kerala, Dept Optoelect, Thiruvananthapuram 695581, Kerala, India
[4] Univ Kerala, Thiruvananthapuram, Kerala, India
关键词
Superparamagnetic iron oxide nanoparticles (SPIONs); Sorafenib; Hepatocellular carcinoma; Apoptosis; Autophagy; Chemotherapy; IRON-OXIDE NANOPARTICLES; CANCER-CELLS; SURFACE MODIFICATION; DRUG-DELIVERY; LIVER-CANCER; TOXICITY; CHEMOTHERAPY; SUBACUTE; CURCUMIN; CARRIERS;
D O I
10.1016/j.lfs.2018.04.046
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Aims: Superparamagnetic iron oxide nanoparticles (SPIONs), as drug delivery vehicles, offer to eliminate the concerns associated with hydrophobic anti-cancer agents. The current study was intended to fabricate a SPION based delivery system for sorafenib that can simultaneously enable targeted delivery of sorafenib and expand its therapeutic index against hepatocellular carcinoma (HCC). Main methods: Co-precipitation and physical entrapment methods were employed for the synthesis of sorafenib loaded PVA coated SPIONs. Physicochemical characterizations were done using TEM, XRD, FTIR, Raman spectra and VSM measurements. The superior activity of nanoconjugate was demonstrated by AO/EB staining, FACS, immunofluorescence and Western blot. The safety of the sorafenib conjugated nanoparticles were verified in Wistar rats. Key findings: The synthesized nanoparticles were in the size range of 5-15 nm. The adsorption of PVA to the SPIONs and the conjugation of sorafenib to the nanocarrier were confirmed by XRD, FTIR and Raman spectra analyses. VSM study ascertained the superparamagnetic nature of the nanoconjugate. Cellular uptake studies suggested its efficient entrapment in HepG2 cells. MTT assay showed that the cytotoxicity of sorafenib loaded PVA/SPIONs was comparable or higher than free sorafenib. The activation of apoptosis and autophagy pathways in HepG2 by the nanoconjugate was evidenced. Acute toxicity testing in Wistar rats supported the safe administration of the nanoconjugate and established its localization in animal tissues by Perl's Prussian Blue reaction. Significance: The novel combination of sorafenib with PVA/SPIONs showed better anticancer efficiency than free sorafenib demonstrative of its potential in cancer chemotherapy.
引用
收藏
页码:10 / 21
页数:12
相关论文
共 50 条
[41]   Simultaneous Inhibition of Tumor Growth and Angiogenesis for Resistant Hepatocellular Carcinoma by Co-delivery of Sorafenib and Survivin Small Hairpin RNA [J].
Shen, Jianan ;
Sun, Huiping ;
Meng, Qingshuo ;
Yin, Qi ;
Zhang, Zhiwen ;
Yu, Haijun ;
Li, Yaping .
MOLECULAR PHARMACEUTICS, 2014, 11 (10) :3342-3351
[42]   Strategies and Recent Advances on Improving Efficient Antitumor of Lenvatinib Based on Nanoparticle Delivery System [J].
Wang, Haiqing ;
Bo, Wentao ;
Feng, Xielin ;
Zhang, Jinliang ;
Li, Ge ;
Chen, Yan .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2024, 19 :5581-5603
[43]   Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma? [J].
Ogasawara, Sadahisa ;
Chiba, Tetsuhiro ;
Ooka, Yoshihiko ;
Kanogawa, Naoya ;
Motoyama, Tenyu ;
Suzuki, Eiichiro ;
Tawada, Akinobu ;
Yokosuka, Osamu .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (06) :1029-1036
[44]   Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection [J].
Kim, Richard ;
Menon, Narayanan ;
Aucejo, Federico .
MEDICAL ONCOLOGY, 2011, 28 (04) :1044-1047
[45]   Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection [J].
Richard Kim ;
Narayanan Menon ;
Federico Aucejo .
Medical Oncology, 2011, 28 :1044-1047
[46]   Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma? [J].
Sadahisa Ogasawara ;
Tetsuhiro Chiba ;
Yoshihiko Ooka ;
Naoya Kanogawa ;
Tenyu Motoyama ;
Eiichiro Suzuki ;
Akinobu Tawada ;
Osamu Yokosuka .
International Journal of Clinical Oncology, 2014, 19 :1029-1036
[47]   Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma [J].
Bohyun Kim ;
Soon Sun Kim ;
Sung Won Cho ;
Jae Youn Cheong ;
Jimi Huh ;
Jai Keun Kim ;
Jei Hee Lee ;
Hye Ri Ahn ;
Hyo Jung Cho .
European Radiology, 2021, 31 :2507-2517
[48]   Liver stiffness in magnetic resonance elastography is prognostic for sorafenib-treated advanced hepatocellular carcinoma [J].
Kim, Bohyun ;
Kim, Soon Sun ;
Cho, Sung Won ;
Cheong, Jae Youn ;
Huh, Jimi ;
Kim, Jai Keun ;
Lee, Jei Hee ;
Ahn, Hye Ri ;
Cho, Hyo Jung .
EUROPEAN RADIOLOGY, 2021, 31 (04) :2507-2517
[49]   Perfusion Magnetic Resonance as a Biomarker for Sorafenib-Treated Advanced Hepatocellular Carcinoma: A Pilot Study [J].
Campos, Marta ;
Candelaria, Isabel ;
Papanikolaou, Nickolas ;
Simao, Adelia ;
Ferreira, Carlos ;
Manikis, Georgios C. ;
Caseiro-Alves, Filipe .
GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2019, 26 (04) :260-267
[50]   Novel biocompatible multifunctional porous magnetic nanoclusters for the targeted delivery of lenvatinib towards hepatocellular carcinoma [J].
Sohail, Saba ;
Zeb, Alam ;
Alamri, Ali H. ;
Fatease, Adel Al ;
Lahiq, Ahmed A. ;
Alruwaili, Nabil K. ;
Khan, Salman ;
Din, Fakhar ud .
MATERIALS ADVANCES, 2025, 6 (05) :1769-1787